Clinical Trial Results:
A prospective, single center, randomized, double-blind, placebo controlled study in two phases to evaluate the safety and efficacy of ATx201 as a topical antibiotic agent
Summary
|
|
EudraCT number |
2016-003501-33 |
Trial protocol |
AT |
Global end of trial date |
12 Mar 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Oct 2019
|
First version publication date |
31 Oct 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
DECOLAD
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
UNION therapeutics A/S (formerly AntibioTx A/S)
|
||
Sponsor organisation address |
Tuborg Havnevej 18, Hellerup, Denmark,
|
||
Public contact |
UNION therapeutics A/S (formerly AntibioTx A/S), UNION therapeutics A/S (formerly AntibioTx A/S), +45 40103044, rasmus.toft-kehler@uniontherapeutics.com
|
||
Scientific contact |
UNION therapeutics A/S (formerly AntibioTx A/S), UNION therapeutics A/S (formerly AntibioTx A/S), +45 40103044, rasmus.toft-kehler@uniontherapeutics.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
11 Jan 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Mar 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study was to demonstrate the safety and tolerability of topical formulations of ATx201 in healthy volunteers and in patients with atopic dermatitis (AD), and to assess efficacy of ATx201 in eradicating S. aureus compared to vehicle after 4 and 7 days of treatment.
To determine the local and systemic exposure of ATx201 (Part 1 and 2) and best tolerable formulation to advance into Part 2 and to assess the impact of ATx201 on AD lesions (Part 2).
|
||
Protection of trial subjects |
Safety and tolerability endpoints (Part 1 and 2): Physical exam, vital signs, ECG (Part 1 only), safety laboratory, number, type and severity of (serious) adverse events (AE), local tolerability assessment scores compared to vehicle.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Nov 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 66
|
||
Worldwide total number of subjects |
66
|
||
EEA total number of subjects |
66
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
66
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
In part 1, 6 additional healthy volunteers were not exposed to the IP and were planned and enrolled for bioanalytical method validation. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
The study was conducted in two Phases. In both Phases of the study subjects were screened at a Screening Visit. Part 1 (Phase 1) consisted of the screening Visit, a 7-day treatment period, and an end of study (EOS) visit on Day 15. Part 2 (Phase 2) consisted of a screening Visit, a 7-day treatment period, and an EOS visit on Day 14. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Part 1
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor | |||||||||||||||
Blinding implementation details |
Unblinded due to their profession were • Responsible staff for preparation of code break envelopes and • Responsible persons for production and labeling of the IP. On Day 8 of Part 1, blinding was broken before biopsy sampling, to detect areas that received active treatment. Routine unblinding of study subjects was prohibited, except for Part 1 in subjects undergoing biopsy sampling. Safety assessments were performed in the morning of Day 8. Biopsy samples were taken after the last application.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Treatment arm 1 | |||||||||||||||
Arm description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
ATx201 Anhydrous Cream 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Anhydrous Cream Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 GEL 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 GEL Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Arm title
|
Treatment arm 2 | |||||||||||||||
Arm description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
ATx201 Anhydrous Cream 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Anhydrous Cream Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Cream 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Cream Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Arm title
|
Treatment arm 3 | |||||||||||||||
Arm description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
ATx201 GEL 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 GEL Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Cream 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 Cream Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each subject in Part 1 was treated with four formulations (two active formulations and their corresponding vehicles). The IPs were applied to defined skin areas in the dorsal arms twice daily. The body area to be treated was circle marked with a skin marker and had a size of 5 cm in diameter. The expected dose of 80-200 mg of the dermal formulation corresponds to 1.6-4.0 mg active substance/day.
|
|||||||||||||||
Arm title
|
Method testing arm | |||||||||||||||
Arm description |
Six healthy volunteers were enrolled for method testing. | |||||||||||||||
Arm type |
method testing- non IMP arm | |||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
|||||||||||||||
|
||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: In part 1 36 healthy subjects were enrolled, in part 2 36 patients with atopic dermatitis. In total 72 patients were enrolled in trial. |
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
Part 2
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor | |||||||||||||||
Blinding implementation details |
On Day 8 of Part 1, blinding was broken before biopsy sampling, in order to detect the areas that received active treatment.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Treatment arm 1 | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
ATx201 GEL 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each patient applied ATx201 GEL 2% and matching vehicle to defined treatment areas between 10-200 cm2 once daily.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 GEL Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each patient applied ATx201 GEL 2% and matching vehicle to defined treatment areas between 10-200 cm2 once daily.
|
|||||||||||||||
Arm title
|
Treatment arm 2 | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
ATx201 GEL 2%
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each patient applied ATx201 GEL 2% and matching vehicle to defined treatment areas between 10-200 cm2 twice daily.
|
|||||||||||||||
Investigational medicinal product name |
ATx201 GEL Vehicle
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Gel
|
|||||||||||||||
Routes of administration |
Cutaneous use
|
|||||||||||||||
Dosage and administration details |
Each patient applied ATx201 GEL 2% and matching vehicle to defined treatment areas between 10-200 cm2 twice daily.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment arm 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment arm 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment arm 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Method testing arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Six healthy volunteers were enrolled for method testing. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Part 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
30 healthy subjects received three formulations of ATx201 and vehicle. The treatment part of Part 1 consisted of a screening visit (Day 0), a randomization visit (Day 1, first treatment), a treatment period of 7 consecutive days (Days 1-7), a PK visit (Day 8), and an EOS (end of study) visit (Day 15±2 days).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Part 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
36 patients (18 patients per group (once-daily vs twice-daily group) with a randomization ratio 1:1 with AD and colonized by S. aureus were enrolled.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment arm 1
|
||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||
Reporting group title |
Treatment arm 2
|
||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||
Reporting group title |
Treatment arm 3
|
||
Reporting group description |
Consisted of the screening Visit, a 7-day treatment period (subjects received two formulations of ATx201 and vehicle), and an end of study (EOS) visit on Day 15. Subjects were treated in 4 separate areas, 2 on the right arm and 2 on the right or left arm, twice daily at the study site. For the subjects biopsies were set on Day 8, one hour after 15th application (±10 minutes) of the IP. | ||
Reporting group title |
Method testing arm
|
||
Reporting group description |
Six healthy volunteers were enrolled for method testing. | ||
Reporting group title |
Treatment arm 1
|
||
Reporting group description |
- | ||
Reporting group title |
Treatment arm 2
|
||
Reporting group description |
- | ||
Subject analysis set title |
Part 1
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
30 healthy subjects received three formulations of ATx201 and vehicle. The treatment part of Part 1 consisted of a screening visit (Day 0), a randomization visit (Day 1, first treatment), a treatment period of 7 consecutive days (Days 1-7), a PK visit (Day 8), and an EOS (end of study) visit (Day 15±2 days).
|
||
Subject analysis set title |
Part 2
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
36 patients (18 patients per group (once-daily vs twice-daily group) with a randomization ratio 1:1 with AD and colonized by S. aureus were enrolled.
|
|
||||||||||||||||
End point title |
Primary efficacy endpoint Day 4 (Part 2) ATx201 GEL 2% [1] | |||||||||||||||
End point description |
Treatment success was defined as a 100-fold reduction in the S. aureus CFU/cm2 of samples skin lesion on Day 4. Once-daily group is Treatment arm 1 and the Twice-daily group is Treatment arm 2. Treatment for both treatment arms: ATx201 Gel 2%.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
After 4 days of treatment.
|
|||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical hypotheses were tested. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Primary safety and tolerability endpoint [2] | ||||||||||||
End point description |
Neither Part 1 or Part 2 demonstrated any safety concerns. The safety endpoint was achieved. No systemic AEs were reported related to the study treatment. Skin reactions were reported as related to the study treatment.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Overall trial
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical hypotheses were tested. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Primary efficacy endpoint Day 7 (Part 2) ATx201 GEL 2% [3] | |||||||||||||||
End point description |
Treatment success was defined as a 100-fold reduction in the S. aureus CFU/cm2 of samples skin lesion on Day 7. Once-daily group is treatment arm 1 and the twice-daily group is treatment arm 2. Treatment for both treatment arms: ATx201 Gel 2%.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
After 7 days of treatment.
|
|||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical hypotheses were tested. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Primary efficacy endpoint Day 4 (Part 2) Vehicle [4] | |||||||||
End point description |
Treatment success was defined as a 100-fold reduction in the S. aureus CFU/cm2 of samples skin lesion on Day 4. Once-daily group is Treatment arm 1 and the Twice-daily group is Treatment arm 2. Treatment for both treatment arms: Vehicle.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
After 4 days of treatment.
|
|||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical hypotheses were tested. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Primary efficacy endpoint Day 7 (Part 2) Vehicle [5] | |||||||||
End point description |
Treatment success was defined as a 100-fold reduction in the S. aureus CFU/cm2 of samples skin lesion on Day 7. Once-daily group is Treatment arm 1 and the Twice-daily group is Treatment arm 2. Treatment for both treatment arms: Vehicle.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
After 7 days of treatment.
|
|||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical hypotheses were tested. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Secondary efficacy endpoint (Part 2) | |||||||||||||||||||||
End point description |
Relative decrease of S. aureus colonies/cm2 on treated skin after treatment of the active groups, relative to their vehicles as well as relative to the untreated area. The Once-daily group is the Treatment arm 1 and the Twice-daily group is the Treatment arm 2.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
The ratio of colony count was measured on Day 7 compared to Baseline.
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Overall trial (Part 1 and Part 2).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Part 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Part 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
27 Apr 2017 |
The address of the sponsor was amended. Additional 10 patients were planned for an extended pharmokinetic study. Therefore these patients got a higher payment for participation. Additional inclusion criteria were added, i.e. colonisation of lesions with S. aureus. Inclusion criteria were canceled, i.e. caffeine and tobacco consumption. Exclusion criteria were amended, i.e. concomitant medication was extended. Additional two co-workers were added to the protocol. |
||
30 May 2017 |
Participation time of patients was reduced for two days. The overall time of the clinical trial was reduced for one month. Additional inclusion criteria were defined. Additional 3 co-workers were included. The number of S.aureus swabs was increased. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |